Skip to contents

  1. Wierda, William G.; Dorritie, Kathleen A.; Munoz, Javier; Stephens, Deborah M.; Solomon, Scott R.; Gillenwater, Heidi H.; Gong, Lucy; Yang, Lin; Ogasawara, Ken; Thorpe, Jerill; Siddiqi, Tanya

    Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

    Articles
    View online
    Close

    Bookmarks

    You can manage bookmarks using lists, please log in to your user account for this.

    American Society of Hematology, 2020

    Published in: Blood

  2. Siddiqi, Tanya; Dorritie, Kathleen Anne; Soumerai, Jacob Drobnyk; Stephens, Deborah Marie; Dubovsky, Jason A; Gillenwater, Heidi H.; Gong, Lucy; Thorpe, Jerill; Yang, Lin; Wierda, William G.

    TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)

    Articles
    View online
    Close

    Bookmarks

    You can manage bookmarks using lists, please log in to your user account for this.

    American Society of Clinical Oncology (ASCO), 2019

    Published in: Journal of Clinical Oncology

  3. Siddiqi, Tanya; Soumerai, Jacob D.; Wierda, William G.; Dubovsky, Jason A.; Gillenwater, Heidi H.; Gong, Lucy; Mitchell, Alan; Thorpe, Jerill; Yang, Lin; Dorritie, Kathleen A.

    Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

    Articles
    View online
    Close

    Bookmarks

    You can manage bookmarks using lists, please log in to your user account for this.

    American Society of Hematology, 2018

    Published in: Blood